Breaking News

A convicted sex offender and gang member apprehended by Laredo Sector Border Patrol NASA to Provide Live Coverage of US Spacewalks Outside Space Station City of St. Louis Scores 100 on Human Rights Campaign’s Municipal Equality Index for 11th Year in a Row Intuit Inc. – Intuit Accountants Announces New Products Updates for Tax Year 2022 Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases The Mary Eliza Project: South Boston Voter Records Now Available Collaborative Efforts Yield 52 Individuals at Laredo Sector EPA finds Denver Water’s Lead Reduction Program effective

Issued: London UK

GlaxoSmithKline (GSK) today announced the appointment of Patrick Vallance, as Senior Vice President, Medicines Discovery and Development and as a member of the company’s Corporate Executive Team both with effect from 1st July 2010.

Andrew Witty, Chief Executive Officer, GSK commented: “Patrick has a deep level of scientific and medical acumen, which coupled with his proven management skills, mean he is well placed to bring further R&D perspective to GSK’s leadership team. This appointment aligns with the company’s drive to increase R&D productivity and deliver more products of value. I look forward to working with Patrick in his new role and welcome him to the executive team.”

Prior to joining GSK in 2006, Patrick was a clinical academic and led the Division of Medicine at UCL. He has over 20 years of experience of clinical medicine and has an international reputation as a vascular biologist and clinician scientist. He was elected to the Academy of Medical Sciences in 1999, and subsequently became its Registrar before leaving to join GSK.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

GlaxoSmithKline Enquiries:


UK Media enquiries:

Philip Thomson

(020) 8047 5502


Claire Brough

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502


Jo Revill

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839



European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill Baxter

(215) 751 7002

Source link